RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
République de Corée, Cheonan
La clinique est certifiée :
Le traitement de la sclérose en plaques par cellules souches en Corée du Sud coûte entre $52,000 et $85,000. Le prix final dépend de la méthode d'administration, de la source des cellules et de la complexité du protocole. En France, ces soins coûtent environ $60,000. Les patients économisent environ 13% par rapport aux tarifs français. Les prestations incluent généralement les consultations, la préparation cellulaire, l'administration et le suivi médical.
Avis d'expert Bookimed : Choisir une clinique utilisant des méthodes d'administration ciblées peut optimiser les bénéfices thérapeutiques. Le centre RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) à Cheonan est le seul établissement coréen spécialisé en thérapie artérielle. Cette approche injecte les cellules directement dans les organes cibles pour une meilleure assimilation. Bien que spécialisée, elle offre un excellent rapport qualité-prix pour les pathologies neurologiques. Cet établissement est accrédité par le programme KOIHA et traite 1 000 patients par an. Des neurologues experts comme le Dr Yeon Jung Kim, formé à l'Asan Medical Center, dirigent ces interventions complexes.
Pourquoi envisager la République de Corée pour un traitement par cellules souches de la sclérose en plaques (SEP) ?
Accédez à des solutions avancées de traitement par cellules souches pour la sclérose en plaques (SEP) dans des cliniques de confiance .
| République de Corée | Turquie | Espagne | |
| Traitement de la sclérose en plaques par cellules souches | de $52,000 | de $12,000 | de $30,000 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Traitement de la sclérose en plaques par cellules souches. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Traitement de la sclérose en plaques par cellules souches.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Traitement de la sclérose en plaques par cellules souches et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Traitement de la sclérose en plaques par cellules souches.
Stem cell treatment for multiple sclerosis in South Korea is highly regulated and generally safe within accredited hospitals. Accredited centres follow KOIHA standards, meeting international safety protocols. Primary risks involve chemotherapy conditioning during haematopoietic stem cell transplantation (HSCT). These include infection, infertility, or transplant complications.
Bookimed Expert Insight: Many countries focus on general infusions. However, South Korean clinics like RE:YOUTH offer specific arterial stem cell therapy. This method targets damaged areas more directly. Monitoring is strict. Some VIP clinics limit intake to just 2 patients daily to maintain safety.
Patient Consensus: Patients find that the chemotherapy conditioning is the most physically demanding phase. They suggest confirming the exact protocol with an Australian neurologist before travelling to South Korea.
Ideal candidates for MS stem cell treatment in South Korea typically have Relapsing-Remitting MS (RRMS) with active inflammatory disease. Specialists look for patients showing frequent relapses or new MRI lesions despite standard medication. An EDSS score between 3.0 and 6.0 generally leads to the best outcomes. EDSS stands for Expanded Disability Status Scale.
Bookimed Expert Insight: Most clinics focus on intravenous delivery. However, RE:YOUTH in Cheonan provides arterial stem cell therapy. This method can target specific areas more directly than standard infusions. Clinics like this often limit intake to only 2 patients daily. This helps maintain high standards for complex neurological cases.
Patient Consensus: Patients suggest bringing a complete MRI history and EDSS records. This speeds up the eligibility process. They highlight that Republic of Korea clinics excel at managing early, aggressive cases. Their strength lies in specialised immune reconstitution.
Stem cell therapy in South Korea is not a permanent cure for multiple sclerosis. Treatments like haematopoietic stem cell transplant (HSCT) can halt disease activity for years. However, no clinical evidence proves it permanently eliminates the condition. Clinics focus on slowing progression and reducing relapse frequency.
Bookimed Expert Insight: General stem cell infusions start from $800. However, dedicated MS protocols in South Korea range up to $85,000. Patients should distinguish between simple regenerative infusions and clinical HSCT. Only HSCT with chemotherapy currently has a proven evidence base for halting MS progression.
Patient Consensus: Evidence in Republic of Korea supports HSCT for halting relapses for years. However, existing damage often remains. Patients suggest checking if a clinic offers published outcomes specifically for their MS subtype.
South Korea offers specialised stem cell therapies for multiple sclerosis. These focus on delivery methods like arterial stem cell therapy. This intensive treatment bypasses typical intravenous routes. It aims for direct infusion to target neurological damage. Facilitated by KOIHA-accredited specialists, these protocols serve patients seeking regenerative medicine alternatives.
Bookimed Expert Insight: While many countries offer standard intravenous drips, South Korean clinics often specialise in direct arterial delivery. This method aims to overcome the blood-brain barrier which often limits traditional IV treatments. Focusing on centres that limit daily patient numbers means more precise monitoring during these complex infusions.
Patient Consensus: Patients find that South Korea's high-tech clinics provide a professional environment for experimental therapies. Many recommend verifying if protocols include chemotherapy or just cell injections to manage expectations.
Stem cell treatment for MS in South Korea follows a strict medical protocol. It focuses on immune system recalibration. The process involves harvesting a patient’s own stem cells. Intensive therapy resets the immune system. Then the cells are reintroduced to halt disease progression. This takes place in Korea Medical Institute‑accredited facilities.
Bookimed Expert Insight: Data suggests that highly specialised clinics like RE:YOUTH limit intake to just 2 patients daily. This VIP‑level focus means intensive monitoring during the critical arterial infusion phase. Such individual attention is vital when managing the complex immune responses typical of MS patients.
Patient Consensus: South Korea is chosen for its focus on stopping relapses rather than only repairing damage. Patients note that recovery takes 1–2 years. It stops progression effectively for relapsing‑remitting MS.
Choosing a clinic in South Korea for MS stem cell treatment requires two things. Verify KOIHA (Korean International Healthcare Association) accreditation and specialised delivery methods. Seek facilities offering direct arterial stem cell infusion, which targets lesions specifically. Prioritise clinics limiting daily patient numbers for personalised medical supervision.
Bookimed Expert Insight: While many centres use intravenous drips, South Korea leads in arterial stem cell infusion. This method delivers cells directly through the artery to target nervous system damage. Data shows specialised clinics like RE:YOUTH focus on this high-precision approach for better results.
Patient Consensus: Patients value how Korean clinics coordinate every step from airport pickup to multilingual support. They highlight the comfort of VIP care. They also note the thoroughness of initial arterial diagnostic scans.